AKT1 and cancer: Kyoto encyclopedia of genes and genomes pathway enrichment revealed that many pathways known to be associated with the response to anti‐PD‐L1 therapy, such as the WNT pathway,[29] PI3K‐AKT pathway,[30] PD‐L1 expression and PD‐1 checkpoint pathway in cancer,[31] MAPK pathway,[32] NF‐kappa B signaling pathway,[33] and TP53 pathway,[16] were significantly enriched (Figure 2D).